(Total Views: 99)
Posted On: 06/14/2019 9:50:41 AM
Post# of 15393
$ARQL News Article - ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting https://marketwirenews.com/news-releases/arqu...55712.html
(0)
(0)
My Twitter: WhyteStocks
Scroll down for more posts ▼
